<< Back
September 25, 2017 at 8:00 AM EDT

Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer

BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 25, 2017-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Donald Notman as Chief Financial Officer, effective immediately. With over 20 years of financial operations and senior-level investment banking experience, Mr. Notman brings a distinguished track record of success to Ocular Therapeutix. Mr. Notman will replace interim CFO George Migausky and will be responsible for all strategic financial planning and reporting and investor relations. He will also support the Company’s business development initiatives.

“Donald brings an extensive financial background as well as a wealth of experience and relationships ideally suited to Ocular Therapeutix,” said Antony Mattessich, President and Chief Executive Officer. “He will be a strong complement to our existing team and his expertise will be invaluable as we focus our efforts on leveraging our hydrogel technology platform to build a leading biopharmaceutical company. We would also like to thank George for his many contributions as interim CFO over the last several months and wish him all the best.”

Prior to joining Ocular Therapeutix, Mr. Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the Company’s financial operations, business development activities, and strategic planning functions. Previously, Mr. Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Mr. Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Mr. Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.

“Ocular’s innovative hydrogel technology platform along with the team’s formulation and product development expertise provide Ocular with the ability to leverage the platform in a number of ways to advance the Company,” stated Mr. Notman. “I look forward to applying my background and expertise to help Ocular achieve its full potential.”

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company including the development and regulatory status of the Company’s product candidates, such as the Company’s expectations and plans regarding product development efforts and regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA for the treatment of post-surgical ocular inflammation and pain, including with respect to the manufacturing deficiencies identified by the FDA and the prospects for approvability of DEXTENZA for these indications, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for the treatment of dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing development of the Company’s sustained release intravitreal depot, the potential utility of any of the Company’s product candidates, potential commercialization of the Company’s product candidates, the sufficiency of the Company’s cash resources, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s manufacturing operations, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the availability of cash resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Source: Ocular Therapeutix, Inc.

Burns McClellan
Steve Klass, 212-213-0006
Ocular Therapeutix
Donald Notman
Chief Financial Officer
Ocular Therapeutix
Scott Corning
Vice President of Marketing & Commercial Operations